Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07099924

Rectus Sheath Catheters Following Midline Laparotomy

Rectus sheath catheters (RSC) are used for postoperative analgesia following midline laparotomies. Local anesthetics are applied to the posterior rectus sheath via the RSC. The target structures are the anterior cutaneous branches of the spinal nerves Th7-Th12. RSC can be used in particular if thoracic epidurals are contraindicated (compromised coagulation), technically unfeasible or refused by the patient.

The study investigates placebo-controlled weather RSC have a significant additional analgesic effect in a multimodal analgesic concept. Primary outcome parameters are the maximum pain score, the Quality-of-Recovery-15-Score (QoR-15GE) and the opioid consumption (morphine equivalents) in the first 72h postoperatively.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Asklepios Medical Center Uckermark

Schwedt, Brandenburg, 16303, Germany

Location contact

Ronald Seidel, Dr.med.

PRINCIPAL_INVESTIGATOR

Rüdiger Heicappell, Prof.

CONTACT

[email protected]

+493332530

Torsten Joerres

CONTACT

[email protected]

About this study

Recruitment Patients are recruited during the anesthesiology consultation. Patients who provided written informed consent. fulfill all inclusion and no exclusion criteria will be included in the study.

Allocation of study medication After inclusion in the study, each patient receives a patient number, which is noted on the Case Report Form (CRF). The randomization list was generated via www.random.org (Randomness and Integrity Services Ltd., Dublin, Ireland). Random assignment to groups 1 (verum) and 2 (placebo) was performed on the day of surgery using the sealed envelope technique. The sealed envelope is opened by a doctor not involved in the study immediately before bilateral placement of the rectus catheters catheters. This colleague prepares the study medication (verum or placebo, unlabeled, blinded to the observer and patient).

Anesthesia and perioperative monitoring After a peripheral or central venous line is inserted, a balanced electrolyte solution is connected and the following parameters are monitored until complete postoperative recovery: blood pressure (plethsymographic or via arterial line), electrocardiogram, pulse oximetry.

The surgical procedures are performed under general anesthesia (sevoflurane 0.7-1.0 MAC). Sufentanil (0.2-0.4 microg/kg), propofol (1.5-2 mg/kg) and cisatracurium (0.1-0.15 mg/kg) are administered to induce anesthesia The multimodal analgesia concept includes the intraoperative administration of 4 mg dexamethasone (antiemetic, coanalgesic) and two non-opioids: 1 g metamizole (40 mg parecoxib if contraindications exist) and 1 g paracetamol.

Study intervention Bilateral RSC are placed intraoperatively after closure of the median laparotomy under aseptic conditions, before the wound dressing is applied. For imaging, we use an ultrasound device (FUJIFILM Sonosite, Bothel, WA, USA) with a linear transducer (38mm, 6-13MHz), which is placed obliquely on the upper edge of the median laparotomy. The puncture (puncture direction from medial-cranial to lateral-caudal) is initially performed with an ultrasound-optimized single-shot cannula (SonoPlex 22G50mm to 21G100mm, Pajunk, Geisingen, Germany) in order to reliably identify the compartment of the posterior rectus sheath. After verification of the correct spread of the local anesthetic, the catheter (SonoLong Echo 19G 50-100mm, 20G 50cm catheter, Pajunk, Geisingen, Germany) is placed at the lateral edge of the posterior rectus sheath and again the correct spread of the local anesthetic in the target compartment is verified by ultrasound.

Group 1 Verum (ropivacaine 0.2%) Dosage 2x30ml ropivacaine 0.2% every 8h (120mg every 8h) Daily dose 360mg

Group 2 Placebo (saline 0.9%) Dosage 2x30ml saline 0.9% every 8h

Postoperative care Postoperatively, patients are cared for in the recovery room or intensive care unit. As soon as their condition allows, they are transferred to a peripheral ward. Non-opioid analgesics are continued. An additional opioid-based on-demand medication is prescribed (7.5 mg piritramid), the dose of which is documented as morphine equivalents (5 mg).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Median laparotomy
  • Age over 18 years
  • Informed consent has been obtained

Exclusion criteria

  • Local signs of inflammation
  • known allergy to local anesthetics used
  • chronic pain syndrome
  • drug addiction
  • post-operative ventilation that cannot be completed on the day of surgery
  • lack of consent or cooperation
  • pregnancy
  • participation in another medical study
  • sepsis

Treatment and study plan

Ropivacaine 0.2%

Drug

2x30ml (bilateral) ropivacaine 0.2% every 8 hours via rectus sheath catheter

Other names: local anesthetic

saline 0.9%

Drug

2x30ml saline 0.9% every 8 hours via rectus sheath catheter

Other names: placebo

Primary outcomes

  1. patient satisfaction

    Time frame: on first postoperative day

    Quality-of-Recovery Score 15, minimum value 0, maximum value 150, higher values mean a better outcome

  2. pain score (numeric rating scale)

    Time frame: daily up to 72 hours postoperatively

    at rest and at movement, minimum value 0, maximum value 10, lower values mean a better outcome

  3. Opioid consumption

    Time frame: on the day of surgery, on the first postoperative day, on the second postoperative day, on the third postoperative day

    cumulative morphine equivalents

Secondary outcomes

  1. postoperative complications

    Time frame: up to 14 days from date of randomization

    Number of participants experiencing the following postoperative complications:

    nausea and vomiting, constipation, respiratory failure, pneumonia, wound infections, wound dehiscence

Study contacts

Contact information is provided by the study sponsor or research team.

Ronald Seidel, Dr.med.

CONTACT

[email protected]

+49 3332 534521

Sponsors and collaborators

Lead sponsor

Asklepios Kliniken Hamburg GmbH

Other

Registry information

Official study title

Bilateral Rectus Sheath Catheters Following Midline Laparotomy. A Randomized, Placebo-controlled Trial

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 1, 2025
Registry last updated
Aug 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.